News|Videos|January 31, 2025
Clinical Management of Cytokine Release Syndrome in CAR-T Therapy
Expert panelists explore approaches to grading and managing Cytokine Release Syndrome (CRS) in CAR-T therapy, discussing effective strategies to mitigate severity and key differences in CRS management protocols between ide-cel and cilta-cel.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Cytokine Release Syndrome (CRS) is a major concern in CAR-T therapy. How do you approach the grading and management of CRS?
- Which strategies have you found most effective for reducing the severity of CRS?
- Are there notable differences in CRS management protocols between ide-cel and cilta-cel?
Advertisement
Related to this article
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
How AI Could Ease the Cost Crisis in Cancer Care
3
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
4
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
5